Previous close | 172.75 |
Open | N/A |
Bid | 244.95 |
Ask | 253.60 |
Strike | 620.00 |
Expiry date | 2024-11-15 |
Day's range | 172.75 - 172.75 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Nvidia’s fight to remain the world’s most valuable company begins, disappointing retail sales raise hopes for a September rate cut, and more news to start your day.
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Moody's released a new report Tuesday that reins in Wall Street expectations for the impact of GLP-1s on other industries.